



Correction

Correction: Santonocito et al. Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer's Disease: Formulation Development and Optimization. *Nanomaterials* 2021, 11, 391

Debora Santonocito ^{1,†}, Giuseppina Raciti ^{1,†}, Agata Campisi ¹, Giovanni Sposito ¹, Annamaria Panico ¹, Edy Angela Siciliano ¹, Maria Grazia Sarpietro ¹, Elisabetta Damiani ² and Carmelo Puglia ^{1,*}

¹ Department of Drug Science and Health, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy; debora.santonocito@outlook.it (D.S.); racitigi@unict.it (G.R.); agcampisi@gmail.com (A.C.); giovanni.sposito@hotmail.it (G.S.); panico@unict.it (A.P.); edysiciliano@hotmail.it (E.A.S.); mg.sarpietro@unict.it (M.G.S.)

² Department of Life and Environmental Sciences, Polytechnic University of Marche, 60121 Ancona, Italy; e.damiani@univpm.it

* Correspondence: capuglia@unict.it; Tel.: +39-0957-384-206

† These authors equally contributed to the work.



Citation: Santonocito, D.; Raciti, G.; Campisi, A.; Sposito, G.; Panico, A.; Siciliano, E.A.; Sarpietro, M.G.; Damiani, E.; Puglia, C. Correction: Santonocito et al. Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer's Disease: Formulation Development and Optimization. *Nanomaterials* 2021, 11, 391. *Nanomaterials* 2023, 13, 3088. <https://doi.org/10.3390/nano13243088>

Received: 27 July 2023

Accepted: 25 October 2023


Published: 6 December 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Error in Figure

In the original publication [1], there was a mistake in Figure 3b as published. An error was committed during the preparation of the manuscript “Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer's Disease: Formulation Development and Optimization”, in which the image in Figure 3b is similar to Figure 2a from another article, “Curcumin Containing PEGylated Solid Lipid Nanoparticles for Systemic Administration: A Preliminary Study” published in *Molecules*. The corrected Figure 3b appears below.



The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the academic editor. The original publication has also been updated.

Reference

1. Santonocito, D.; Raciti, G.; Campisi, A.; Sposito, G.; Panico, A.; Siciliano, E.A.; Sarpietro, M.G.; Damiani, E.; Puglia, C. Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer's Disease: Formulation Development and Optimization. *Nanomaterials* **2021**, *11*, 391. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.